Risk of secondary progression in patients with highly active multiple sclerosis treated with natalizumab: a real-life study
Journal of Neurology · 2024
DOI: 10.1007/s00415-024-12266-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neurology, 2024. Verfasst von Louisa Scherer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Nancy University Hospital, 54035, Nancy, France. Hauptthemen laut MEDLINE: Natalizumab, Disease Progression, Immunologic Factors, Registries. Die Arbeit nennt 33 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: one of the most important therapeutic goals in relapse-onset multiple sclerosis is to preclude conversion to secondary progression. Our objective was to determine the risk of progression associated with natalizumab treatment in an registry-based cohort of patients and to identify determinant factors. METHODS: Patients with relapse-onset multiple sclerosis from the Registre Lorrain des Scléroses en Plaques (ReLSEP) were included if they had received one infusion of natalizumab between 2002 and 2021. The risk of secondary progression was determined using a standardized definition and a multi-state estimator to account for the possibility of stopping natalizumab before progression, and analyzed with multivariate Cox models. RESULTS: 574 patients were followed up for a median of 6.7 years. Of the 304 who stopped NTZ before progression onset, the probabilities (95% confidence interval) to convert to progression after 1, 2, 5 and 10 years were 3.2% (2.0-4.8%), 5.3% (3.6-7.3%), 17.5% (14.3-21.3%) and 28.3% (23.7-33.7%), respectively. Discontinuation of NTZ during follow-up was significantly associated with an increased risk of conversion in case of no resumption of a highly active treatment thereafter (adjusted hazard ratio = 2.7; 95% confidence interval 1.5-4.9; p = 0.001). The use of such a treatment was associated with a lower risk of progression (adjusted hazard ratio = 0.42; 95% confidence interval 0.23-0.79; p = 0.007). CONCLUSION: the risk of conversion to secondary progression associated with natalizumab treatment is relatively low but increases in case of natalizumab discontinuation in the absence of switch to highly active immunosuppressant.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Nancy University Hospital, 54035, Nancy, France.
- CIC, Epidémiologie Clinique, CHRU-Nancy, Université de Lorraine, 54000, Nancy, France.
- Université de Lorraine, INSPIIRE, INSERM, 54000, Nancy, France.
- Department of Neurology, Nancy University Hospital, 54035, Nancy, France. g.mathey@chru-nancy.fr.
- Université de Lorraine, INSPIIRE, INSERM, 54000, Nancy, France. g.mathey@chru-nancy.fr.
Zitieren
APA
Scherer, L., Soudant, M., Pittion-Vouyovitch, S., Debouverie, M., Guillemin, F., Epstein, J., & Mathey, G. (2024). Risk of secondary progression in patients with highly active multiple sclerosis treated with natalizumab: a real-life study. Journal of Neurology. https://doi.org/10.1007/s00415-024-12266-8
Vancouver
Scherer L, Soudant M, Pittion-Vouyovitch S, Debouverie M, Guillemin F, Epstein J, et al. Risk of secondary progression in patients with highly active multiple sclerosis treated with natalizumab: a real-life study. Journal of Neurology. 2024. doi:10.1007/s00415-024-12266-8
BibTeX
@article{Scherer2024,
author = {Scherer, Louisa and Soudant, Marc and Pittion-Vouyovitch, Sophie and Debouverie, Marc and Guillemin, Francis and Epstein, Jonathan and Mathey, Guillaume},
title = {Risk of secondary progression in patients with highly active multiple sclerosis treated with natalizumab: a real-life study},
journal = {Journal of Neurology},
year = {2024},
doi = {10.1007/s00415-024-12266-8}
}
EUVIMED